Adding rolapitant improves prevention of chemo-induced nausea, vomiting
the ONA take:
Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well-tolerated and demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the at-risk period following the administration of highly emetogenic cisplatin-based chemotherapy, a new study published online ahead of print in The Lancet Oncology has shown.
Two double-blind, active-controlled, phase 3 trials were conducted to assess rolapitant, a neurokinin-1 receptor antagonist, for the prevention of CINV in patients with cancer in the 120 hours after administration of cisplatin-based chemotherapy.
Patients were randomly assigned to receive either oral rolapitant 180 mg or placebo 1 to 2 hours before cisplatin in conjunction with granisetron and dexamethasone. Results showed that a significantly higher proportion of patients in the rolapitant arms achieved completes responses during the delayed phase than did patients who received placebo.
In regard to safety, no serious treatment-emergent adverse events were related to rolapitant treatment.
The findings suggest that adding rolapitant to granisetron and dexamethasone is superior to granisetron and dexamethasone alone for the prevention of CINV during the delayed phase after receiving cisplatin-based chemotherapy.
Rolapitant demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer
- Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women
- Live-streamed Videos Address End-of-Life Planning, Decision-making
- Metastatic Disease Linked to Patients Reporting Diminished QoL
- History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis
- Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|